Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Transplantation and cellular therapy·2026
Same author

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same author

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Blood cancer journal·2026
Same author

Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell Disease.

The New England journal of medicine·2026
Same author

Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.

Transplantation and cellular therapy·2026
Same author

Statistical Methods for Chimeric Antigen Receptor Cell Therapy Outcomes: A Review and Practical Considerations.

Transplantation and cellular therapy·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.0K

Endpoint selection and evaluation in hematology studies.

Ruta Brazauskas1, Mary Eapen2, Tao Wang1

  • 1Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.

Best Practice & Research. Clinical Haematology
|August 23, 2023
PubMed
Summary
This summary is machine-generated.

This review details common outcomes and endpoints for hematologic disease studies, emphasizing clinical outcomes for treatment safety and efficacy. It also highlights patient-reported outcomes and provides guidance for selecting primary and secondary endpoints in clinical trials.

Keywords:
Clinical trialsComposite endpointsEndpointsHematologyOutcomesPatient reported outcomesPrimary endpointsSurrogate endpoints

More Related Videos

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.3K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Related Experiment Videos

Last Updated: Jul 18, 2025

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.0K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.3K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Area of Science:

  • Hematology
  • Clinical Trials
  • Biostatistics

Background:

  • Hematology studies evaluate treatments for blood disorders, focusing on outcomes like disease progression, survival, and quality of life.
  • Selecting appropriate endpoints is crucial for meaningful study results and meaningful information about treatment effectiveness.

Purpose of the Study:

  • To review commonly used outcomes and endpoints in hematologic disease research.
  • To provide guidelines for the statistical analysis of these endpoints.
  • To discuss the role of surrogate and composite endpoints and the importance of patient-reported outcomes.

Main Methods:

  • Literature review of observational studies and clinical trials in hematology.
  • Description of frequently used clinical outcomes and endpoints.
  • Discussion of statistical analysis considerations for hematologic endpoints.

Main Results:

  • Identified key clinical outcomes for assessing treatment safety and efficacy in hematologic diseases.
  • Highlighted the significance of patient-reported outcomes for a comprehensive treatment assessment.
  • Provided practical considerations for selecting primary and secondary endpoints.

Conclusions:

  • Appropriate selection and statistical analysis of outcomes and endpoints are vital for hematology clinical trials.
  • Clinical outcomes are central to establishing treatment safety and efficacy.
  • Patient-reported outcomes enhance the comprehensive assessment of treatment effectiveness.